Trevi Therapeutics (TRVI) Change in Acquisitions & Divestments (2022 - 2026)

Trevi Therapeutics has reported Change in Acquisitions & Divestments for 5 years, with the latest figure at $25.6 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments rose 45.22% year-over-year to $25.6 million; the trailing twelve-month figure through Mar 2026 stood at $84.5 million (up 16.76% YoY), and the FY2025 full-year result was $76.6 million, down 0.52% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $25.6 million, up from $23.8 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $25.6 million in Q1 2026, with the low at $12.8 million in Q2 2024.
• Average Change in Acquisitions & Divestments over 5 years is $19.0 million, with a median of $18.8 million recorded in 2023.
• Peak annual rise in Change in Acquisitions & Divestments reached 54.34% in 2024, while the deepest fall reached 35.19% in 2024.
• Tracing TRVI's Change in Acquisitions & Divestments over 5 years: stood at $17.0 million in 2022, then decreased by 18.72% to $13.8 million in 2023, then surged by 54.34% to $21.3 million in 2024, then grew by 11.54% to $23.8 million in 2025, then climbed by 7.42% to $25.6 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $25.6 million (Q1 2026), $23.8 million (Q4 2025), and $20.7 million (Q3 2025), per Business Quant data.

Peer Comparison